10 Most Oversold Penny Stocks to Buy According to Analysts

4. Geron Corporation (NASDAQ:GERN)

Price: $1.64

6-Month Performance: -62.47%

Number of Hedge Fund Holders: 46

Analyst Upside Potential: 204.88% 

Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharmaceutical company focused on developing first-in-class telomerase inhibitors for hematologic malignancies, particularly blood cancers. Its lead product is RYTELO, which is the first FDA-approved telomerase inhibitor for treating certain adult patients with lower-risk myelodysplastic syndromes.

On March 12, analyst Gil Blum of Needham maintained a Buy rating on the stock with a price target of $5. The analyst noted that the European Commission has approved RYTELO for transfusion-dependent anemia in lower-risk MDS patients, strengthening Geron Corporation’s (NASDAQ:GERN) clinical and commercial position. This approval, which follows the FDA’s June 2024 authorization, positions RYTELO as the first telomerase inhibitor in both regions, addressing a high-unmet need for patients ineligible for erythropoietin-based therapies. Blum projects peak EU sales of around $475 million by 2037, driven by reimbursement approvals and expanded access programs. It is one of the most oversold penny stocks to buy according to analysts.